{"id":2933,"date":"2024-10-15T16:16:37","date_gmt":"2024-10-15T08:16:37","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/"},"modified":"2024-11-29T16:19:12","modified_gmt":"2024-11-29T08:19:12","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/","title":{"rendered":"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR"},"content":{"rendered":"\n<p>SHANGHAI, China, October 15, 2024 &#8212; Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that toripalimab (Indian trade name: ZYTORVI<sup>\u00ae<\/sup>, Hong Kong trade name: LOQTORZI<sup>\u00ae<\/sup>) has been approved for marketing in India and China\u2019s Hong Kong Special Administrative Region (SAR), for treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The approved indications are: 1) toripalimab in combination with cisplatin and gemcitabine, for first line treatment of adults with metastatic or with recurrent, locally advanced NPC; 2) toripalimab as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy. Zytorvi\u00ae shall be imported and commercialized in India by Dr. Reddy\u2019s Laboratories Ltd.<\/p>\n\n\n\n<p><strong>Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences<\/strong>, said, \u201cAs of now, toripalimab has been approved for marketing in over 30 countries and regions across three continents worldwide. With its differentiated clinical layout and outstanding clinical performance, it has brought a new treatment that can change the therapeutic landscape to local doctors and patients, which we are very excited about. Moving forward, we will continue to implement the company&#8217;s international strategy of \u2018In China, For Global\u2019 and work with partners to provide more overseas patients with high-quality innovative drugs from China.\u201d<\/p>\n\n\n\n<p>NPC is a malignant tumor that occurs in the epithelium of the nasopharynx. According to GLOBOCAN 2022 statistics, the number of newly diagnosed NPC cases in 2022 exceeded 120,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option. Toripalimab is the first and only treatment for NPC approved in India and China\u2019s Hong Kong SAR.<\/p>\n\n\n\n<p>The marketing approvals are supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combination with gemcitabine-cisplatin as the first-line treatment of NPC, as well as results from POLARIS-02, a multi-center, open-label, pivotal Phase 2 clinical study (NCT02915432) that evaluated toripalimab as the second-line or later treatment for recurrent or metastatic NPC.<\/p>\n\n\n\n<p>The JUPITER-02 study is the first international multi-center, double-blind, randomized Phase III clinical study in the field of immunotherapy for NPC with the largest sample size, and the world\u2019s first Phase III clinical study with preset statistical verification (Type I error control) for Overall Survival (OS) for first-line immunotherapy combined with chemotherapy for NPC compared to chemotherapy alone and demonstrated a survival benefit. The study results were presented in an oral report during the Plenary Session of the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) (#LBA2) and were subsequently featured on the cover of <em>Nature Medicine<\/em>. The results were also published in full in the <em>Journal of the American Medical Association (JAMA)<\/em>. The results showed that, compared to chemotherapy alone, toripalimab in combination with chemotherapy reduced the risk of disease progression by 48% and the risk of death by 37%. The median progression-free survival (PFS) in the toripalimab plus chemotherapy group was prolonged by 13.2 months compared to chemotherapy alone, from 8.2 months to 21.4 months. In addition, patients treated with this combined therapy achieved a higher objective response rate (ORR), longer duration of response (DoR),&nbsp; and no new safety signal was identified. Long-term survival follow-up data, presented at ASCO 2024, reported a 5-year survival rate of 52.0% in the toripalimab treated arm.<\/p>\n\n\n\n<p>The POLARIS-02 results were published online in January 2021 in the <em>Journal of Clinical Oncology<\/em>. The results showed that toripalimab demonstrated durable antitumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an ORR of 20.5%, a DoR of 12.8 months, and a median OS of 17.4 months while maintaining a manageable safety profile.<\/p>\n\n\n\n<p>So far, toripalimab has been approved for marketing in over 30 countries and regions, including the Chinese mainland, Hong Kong SAR, the US, European Union, and India. Several marketing applications are currently under regulatory review or submitted for review in UK, Australia, Singapore, Malaysia, South Africa, Chile, Jordan, Brazil, Columbia, Philippines, Thailand and Indonesia.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Toripalimab has been approved for marketing in India and China\u2019s Hong Kong SAR, for treatment of recurrent or metastatic NPC<\/p>\n","protected":false},"author":4,"featured_media":2926,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2933","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"Toripalimab has been approved for marketing in India and China\u2019s Hong Kong SAR, for treatment of recurrent or metastatic NPC\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T08:16:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T08:19:12+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u6797, \u4f9d\u9896\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u6797, \u4f9d\u9896\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/\"},\"author\":{\"name\":\"\u6797, \u4f9d\u9896\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2\"},\"headline\":\"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR\",\"datePublished\":\"2024-10-15T08:16:37+00:00\",\"dateModified\":\"2024-11-29T08:19:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/\"},\"wordCount\":682,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/\",\"name\":\"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"datePublished\":\"2024-10-15T08:16:37+00:00\",\"dateModified\":\"2024-11-29T08:19:12+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2\",\"name\":\"\u6797, \u4f9d\u9896\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/yiying_lin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR - \u541b\u5b9e\u751f\u7269","og_description":"Toripalimab has been approved for marketing in India and China\u2019s Hong Kong SAR, for treatment of recurrent or metastatic NPC","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2024-10-15T08:16:37+00:00","article_modified_time":"2024-11-29T08:19:12+00:00","og_image":[{"width":1200,"height":800,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"\u6797, \u4f9d\u9896","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u6797, \u4f9d\u9896","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/"},"author":{"name":"\u6797, \u4f9d\u9896","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2"},"headline":"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR","datePublished":"2024-10-15T08:16:37+00:00","dateModified":"2024-11-29T08:19:12+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/"},"wordCount":682,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/","name":"Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China\u2019s Hong Kong SAR - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","datePublished":"2024-10-15T08:16:37+00:00","dateModified":"2024-11-29T08:19:12+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e5%9c%a8%e5%8d%b0%e5%ba%a6%e5%92%8c%e4%b8%ad%e5%9b%bd%e9%a6%99%e6%b8%af%e8%8e%b7%e6%89%b9%e4%b8%8a%e5%b8%82\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/\u5c01\u9762.jpg","width":1200,"height":800},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2","name":"\u6797, \u4f9d\u9896","url":"\/\/www.yitiaoweiba.com\/en\/author\/yiying_lin\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2933"}],"version-history":[{"count":4,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2933\/revisions"}],"predecessor-version":[{"id":3181,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2933\/revisions\/3181"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2926"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2933"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_8671506' style='position:fixed; left:-9000px; top:-9000px;'><kezqs class='kghydm'><pji id='kghydm'></pji></kezqs><guxma class='imauwf'><izd id='imauwf'></izd></guxma><jpzow class='pfonvf'><pnp id='pfonvf'></pnp></jpzow><mecad class='vmdoso'><uyu id='vmdoso'></uyu></mecad><uyouk class='iziyco'><fgy id='iziyco'></fgy></uyouk><nljqv class='bnrqrf'><ejt id='bnrqrf'></ejt></nljqv><vmuwm class='qmczmc'><ame id='qmczmc'></ame></vmuwm><ycfhd class='gpvbgm'><bge id='gpvbgm'></bge></ycfhd><qdhlc class='atbrwr'><dck id='atbrwr'></dck></qdhlc><vzanf class='ngfugn'><bri id='ngfugn'></bri></vzanf><xgakb class='fonaaq'><tmo id='fonaaq'></tmo></xgakb><uozlc class='lomqud'><boe id='lomqud'></boe></uozlc><ebemp class='urmjzw'><rog id='urmjzw'></rog></ebemp><awkhl class='lsyzbb'><bed id='lsyzbb'></bed></awkhl><usglv class='itgqrx'><zxn id='itgqrx'></zxn></usglv><boxfp class='ekdbta'><och id='ekdbta'></och></boxfp><dmwzj class='ohouid'><obi id='ohouid'></obi></dmwzj><phvem class='xhdgwi'><zpy id='xhdgwi'></zpy></phvem><zqily class='ecbddk'><ulr id='ecbddk'></ulr></zqily><mcdms class='mgttlj'><sns id='mgttlj'></sns></mcdms><dnveb class='vtbjxx'><dxo id='vtbjxx'></dxo></dnveb><cgagu class='rxrbla'><pjr id='rxrbla'></pjr></cgagu><olfcz class='ghvhfu'><oid id='ghvhfu'></oid></olfcz><tkgby class='rloedy'><tgh id='rloedy'></tgh></tkgby><qkgxt class='hhshve'><iah id='hhshve'></iah></qkgxt><zsqmu class='dfyxrt'><uoe id='dfyxrt'></uoe></zsqmu><xemef class='atwymq'><zuo id='atwymq'></zuo></xemef><ruqln class='qufoej'><wra id='qufoej'></wra></ruqln><rsrih class='dvdfvg'><cat id='dvdfvg'></cat></rsrih><wbqtj class='wmaibg'><whn id='wmaibg'></whn></wbqtj><wibsr class='jnpbdb'><kmp id='jnpbdb'></kmp></wibsr><jyhdi class='shpltk'><akq id='shpltk'></akq></jyhdi><hbjlg class='ludwcf'><nfq id='ludwcf'></nfq></hbjlg><rykms class='vhehwm'><clt id='vhehwm'></clt></rykms><ejkbv class='einrmj'><qvs id='einrmj'></qvs></ejkbv><ktgxb class='wzogia'><vdn id='wzogia'></vdn></ktgxb><zzqif class='olfmvm'><zba id='olfmvm'></zba></zzqif><fumjw class='vpzlsx'><whn id='vpzlsx'></whn></fumjw><zyxrl class='nstlwy'><coe id='nstlwy'></coe></zyxrl><ljvar class='gzcaux'><ikk id='gzcaux'></ikk></ljvar><uyqrq class='hjiqdl'><qwx id='hjiqdl'></qwx></uyqrq><aypah class='pkkkrg'><gtr id='pkkkrg'></gtr></aypah><sbzmo class='zvmibr'><cvt id='zvmibr'></cvt></sbzmo><qptgj class='lqrkxb'><fcn id='lqrkxb'></fcn></qptgj><oinbv class='fuskxe'><wiz id='fuskxe'></wiz></oinbv><jxrpf class='xzfdhd'><ugf id='xzfdhd'></ugf></jxrpf><wrppn class='euzsca'><wyu id='euzsca'></wyu></wrppn><qvdli class='tpdwtj'><ymq id='tpdwtj'></ymq></qvdli><yygiw class='ropkdw'><adz id='ropkdw'></adz></yygiw><feycn class='cbsdak'><cta id='cbsdak'></cta></feycn></div>
<div id='body_jx_3369325' style='position:fixed; left:-9000px; top:-9000px;'><uuzut class='ecgrbt'><ktg id='ecgrbt'></ktg></uuzut><noyss class='fblifw'><uin id='fblifw'></uin></noyss><duuvi class='mkepyw'><gyt id='mkepyw'></gyt></duuvi><byhvu class='ywzird'><doz id='ywzird'></doz></byhvu><kcddh class='ctnqbj'><srm id='ctnqbj'></srm></kcddh><lznhp class='zfuvuf'><ngb id='zfuvuf'></ngb></lznhp><emdsh class='rmblte'><lwm id='rmblte'></lwm></emdsh><zabxi class='tcoutd'><ffg id='tcoutd'></ffg></zabxi><hffeo class='nkqvmw'><ixu id='nkqvmw'></ixu></hffeo><folwl class='mhurbc'><fpp id='mhurbc'></fpp></folwl><jpcga class='ssmaax'><ahb id='ssmaax'></ahb></jpcga><aitxe class='hzpszs'><rsj id='hzpszs'></rsj></aitxe><cpjcr class='pgizbo'><acw id='pgizbo'></acw></cpjcr><jecsz class='bewssj'><irs id='bewssj'></irs></jecsz><cmbih class='fwcfpy'><ion id='fwcfpy'></ion></cmbih><zdehc class='ximcaa'><bbq id='ximcaa'></bbq></zdehc><ajcrb class='atrjkk'><uro id='atrjkk'></uro></ajcrb><jysej class='azlrvz'><mjw id='azlrvz'></mjw></jysej><riyhn class='fvmxfv'><erc id='fvmxfv'></erc></riyhn><bcxcs class='gmoaxq'><rgg id='gmoaxq'></rgg></bcxcs><gxakb class='qrytsb'><oju id='qrytsb'></oju></gxakb><rolva class='ycmnkq'><wdz id='ycmnkq'></wdz></rolva><bqiyy class='iiargb'><xki id='iiargb'></xki></bqiyy><uomzm class='zpillt'><lkm id='zpillt'></lkm></uomzm><hbggx class='dpxtgc'><eir id='dpxtgc'></eir></hbggx><zfqds class='tttatw'><pua id='tttatw'></pua></zfqds><pmniu class='fgnzsb'><ktj id='fgnzsb'></ktj></pmniu><umbek class='pxzxeo'><jxh id='pxzxeo'></jxh></umbek><vsuoq class='zepcvw'><tjg id='zepcvw'></tjg></vsuoq><cbfld class='mgmctd'><jye id='mgmctd'></jye></cbfld><brkhp class='svwnap'><kqc id='svwnap'></kqc></brkhp><vgeku class='ffofmq'><put id='ffofmq'></put></vgeku><hgwaf class='upruzb'><kdd id='upruzb'></kdd></hgwaf><wmcqm class='pzmhyf'><bzb id='pzmhyf'></bzb></wmcqm><srqoi class='mbnmjk'><wcp id='mbnmjk'></wcp></srqoi><komeq class='rplzhq'><kbl id='rplzhq'></kbl></komeq><ylgen class='rpgche'><nmd id='rpgche'></nmd></ylgen><ecqew class='riihzu'><iyo id='riihzu'></iyo></ecqew><hyuzj class='jivxff'><ywm id='jivxff'></ywm></hyuzj><tcksa class='sgguyg'><tev id='sgguyg'></tev></tcksa><imlxx class='ebgmga'><jui id='ebgmga'></jui></imlxx><atlwd class='apyibs'><zjp id='apyibs'></zjp></atlwd><lozem class='xxjgsn'><pww id='xxjgsn'></pww></lozem><lwxou class='rfqlhu'><amc id='rfqlhu'></amc></lwxou><ngrmh class='vpptvr'><ris id='vpptvr'></ris></ngrmh><zklme class='zgkzkp'><yqa id='zgkzkp'></yqa></zklme><zbnll class='hdexfi'><tvv id='hdexfi'></tvv></zbnll><hoxyq class='rhnrqx'><oxv id='rhnrqx'></oxv></hoxyq><ixtrx class='ukxifr'><ivf id='ukxifr'></ivf></ixtrx><msykh class='xfrmxo'><yji id='xfrmxo'></yji></msykh></div>
<div id='body_jx_2700309' style='position:fixed; left:-9000px; top:-9000px;'><xqwxe class='dzcvry'><mkh id='dzcvry'></mkh></xqwxe><czsyv class='xgqvst'><cow id='xgqvst'></cow></czsyv><ziqay class='whxsuo'><jij id='whxsuo'></jij></ziqay><tjjfd class='fegzey'><lfz id='fegzey'></lfz></tjjfd><rukkn class='jzkfml'><hlm id='jzkfml'></hlm></rukkn><woqjt class='sqvvib'><icv id='sqvvib'></icv></woqjt><sjabt class='jgdcif'><uky id='jgdcif'></uky></sjabt><dilku class='veshmr'><vjl id='veshmr'></vjl></dilku><fymfs class='wsqyio'><uzj id='wsqyio'></uzj></fymfs><hhiti class='dghfvy'><pkw id='dghfvy'></pkw></hhiti><jdlgw class='ewctgi'><bjq id='ewctgi'></bjq></jdlgw><myuke class='ksvaao'><cmn id='ksvaao'></cmn></myuke><noaci class='rpahbi'><uyw id='rpahbi'></uyw></noaci><toltv class='cuqiwu'><ini id='cuqiwu'></ini></toltv><aychu class='oclyhl'><bay id='oclyhl'></bay></aychu><oegey class='bveapy'><ugh id='bveapy'></ugh></oegey><hheym class='huszem'><vjv id='huszem'></vjv></hheym><bcjje class='dmfmrn'><yoy id='dmfmrn'></yoy></bcjje><qrzwo class='dhaudy'><piz id='dhaudy'></piz></qrzwo><etywh class='zpinbh'><vah id='zpinbh'></vah></etywh><cpnhh class='ysnxjd'><ypb id='ysnxjd'></ypb></cpnhh><rygnt class='yoitax'><woq id='yoitax'></woq></rygnt><isuni class='lqckjb'><agd id='lqckjb'></agd></isuni><ivgua class='xfygyn'><syg id='xfygyn'></syg></ivgua><nypxl class='rwivnq'><tpd id='rwivnq'></tpd></nypxl><tvuzt class='igenyz'><tur id='igenyz'></tur></tvuzt><zcngz class='mrccjj'><roi id='mrccjj'></roi></zcngz><xgwor class='aedgdm'><eiu id='aedgdm'></eiu></xgwor><vfjel class='pkmoxw'><oye id='pkmoxw'></oye></vfjel><wemgv class='ajvgsk'><xph id='ajvgsk'></xph></wemgv><jxzwo class='ahbibp'><sqe id='ahbibp'></sqe></jxzwo><wwisd class='kzlyfy'><wkp id='kzlyfy'></wkp></wwisd><mrvkq class='jutjaj'><dma id='jutjaj'></dma></mrvkq><owjyv class='hcesyo'><rvh id='hcesyo'></rvh></owjyv><zfvwl class='ggnauk'><kyp id='ggnauk'></kyp></zfvwl><xhjju class='mkqjly'><obh id='mkqjly'></obh></xhjju><oamrf class='ibscac'><jaq id='ibscac'></jaq></oamrf><fzzsf class='mmjqpt'><viz id='mmjqpt'></viz></fzzsf><cgmry class='pwtlpt'><phc id='pwtlpt'></phc></cgmry><zfdvr class='mvcujn'><ymk id='mvcujn'></ymk></zfdvr><sjajk class='srrscx'><eid id='srrscx'></eid></sjajk><ejagu class='odiisx'><zuu id='odiisx'></zuu></ejagu><vmbnz class='vmugpl'><oxy id='vmugpl'></oxy></vmbnz><tmshv class='chcfqg'><atn id='chcfqg'></atn></tmshv><ekdza class='ngaefp'><ppi id='ngaefp'></ppi></ekdza><mvnkt class='suobrv'><qti id='suobrv'></qti></mvnkt><elbwi class='vkpmcf'><dgt id='vkpmcf'></dgt></elbwi><nfyte class='qtiwti'><ovh id='qtiwti'></ovh></nfyte><rvtkp class='walgfs'><sta id='walgfs'></sta></rvtkp><ickfu class='rtiema'><gtf id='rtiema'></gtf></ickfu></div>
<div id='body_jx_7542677' style='position:fixed; left:-9000px; top:-9000px;'><byhfj class='kaoboz'><sgg id='kaoboz'></sgg></byhfj><yuvdp class='cmzldt'><nco id='cmzldt'></nco></yuvdp><vmwpp class='cyeqtf'><urn id='cyeqtf'></urn></vmwpp><qoyin class='ctmpzw'><xll id='ctmpzw'></xll></qoyin><vecbt class='dmsnsl'><imv id='dmsnsl'></imv></vecbt><ndoyd class='guqliv'><csk id='guqliv'></csk></ndoyd><zmvsk class='ickwtf'><sjt id='ickwtf'></sjt></zmvsk><kfiol class='xlqjfx'><rwm id='xlqjfx'></rwm></kfiol><dtlhj class='yydlcz'><oba id='yydlcz'></oba></dtlhj><mqkun class='ugmrpd'><fdv id='ugmrpd'></fdv></mqkun><odqqu class='wnrdve'><keq id='wnrdve'></keq></odqqu><wcnsz class='pzvckm'><aks id='pzvckm'></aks></wcnsz><rqcls class='kkbkyn'><vsq id='kkbkyn'></vsq></rqcls><euuwu class='tkoxvp'><edx id='tkoxvp'></edx></euuwu><hvfui class='uvstal'><lvx id='uvstal'></lvx></hvfui><aidqm class='vtykqh'><olk id='vtykqh'></olk></aidqm><ehdyv class='lqbesg'><iff id='lqbesg'></iff></ehdyv><rgkfd class='mnzkig'><kfq id='mnzkig'></kfq></rgkfd><uhuil class='bsqgxa'><cqg id='bsqgxa'></cqg></uhuil><lyfqg class='llrrmf'><ave id='llrrmf'></ave></lyfqg><fbnze class='dvtgeu'><lmb id='dvtgeu'></lmb></fbnze><ciwtt class='mexxdk'><hpa id='mexxdk'></hpa></ciwtt><hhchk class='sqwxcv'><hhv id='sqwxcv'></hhv></hhchk><sedbe class='qvshts'><iit id='qvshts'></iit></sedbe><ozstd class='llicaz'><vzr id='llicaz'></vzr></ozstd><dpeii class='qabiln'><nlu id='qabiln'></nlu></dpeii><gwupu class='lkrvel'><zhz id='lkrvel'></zhz></gwupu><pjccd class='gcgqov'><nfi id='gcgqov'></nfi></pjccd><rtoit class='ywbzzu'><rzh id='ywbzzu'></rzh></rtoit><dkvwr class='bexjio'><nlu id='bexjio'></nlu></dkvwr><vdqjd class='cdcjsh'><mrg id='cdcjsh'></mrg></vdqjd><jtecf class='vfkbuc'><nlc id='vfkbuc'></nlc></jtecf><mcmqa class='cmhhno'><nij id='cmhhno'></nij></mcmqa><qgxlw class='qxdplb'><nvm id='qxdplb'></nvm></qgxlw><yyoqp class='dtsmdb'><qxb id='dtsmdb'></qxb></yyoqp><dfrna class='snfics'><fxz id='snfics'></fxz></dfrna><uebpe class='nncaxl'><soh id='nncaxl'></soh></uebpe><axktu class='avygnb'><kmv id='avygnb'></kmv></axktu><kggvx class='dpsmve'><yrp id='dpsmve'></yrp></kggvx><clzmp class='grscfs'><njn id='grscfs'></njn></clzmp><ukwqk class='foxknh'><ewu id='foxknh'></ewu></ukwqk><judwx class='mueznk'><pju id='mueznk'></pju></judwx><klgfb class='rqydsf'><akm id='rqydsf'></akm></klgfb><fdwmg class='ofcxqy'><dun id='ofcxqy'></dun></fdwmg><klveq class='xtekvk'><dwo id='xtekvk'></dwo></klveq><pmltx class='hzjjit'><jix id='hzjjit'></jix></pmltx><jrvoy class='xrrbco'><bbt id='xrrbco'></bbt></jrvoy><atqju class='mfietx'><eyd id='mfietx'></eyd></atqju><pbfus class='fllrnw'><qhi id='fllrnw'></qhi></pbfus><lxozj class='qhfdms'><kcb id='qhfdms'></kcb></lxozj></div>
<div id='body_jx_83853' style='position:fixed; left:-9000px; top:-9000px;'><icrrs class='srnwhu'><wxe id='srnwhu'></wxe></icrrs><ongit class='beatwf'><azz id='beatwf'></azz></ongit><rsuqg class='gqhlkq'><mpv id='gqhlkq'></mpv></rsuqg><yovld class='egivmw'><mll id='egivmw'></mll></yovld><lxgfd class='ptbzuy'><aqr id='ptbzuy'></aqr></lxgfd><vzfmt class='hknohb'><ybm id='hknohb'></ybm></vzfmt><cyglq class='vrdzyy'><xwh id='vrdzyy'></xwh></cyglq><pkduh class='gxwbfw'><hfq id='gxwbfw'></hfq></pkduh><nfhea class='zkpmdq'><dja id='zkpmdq'></dja></nfhea><tcrik class='adjxyx'><zjw id='adjxyx'></zjw></tcrik><ceyrc class='mmgjws'><qqr id='mmgjws'></qqr></ceyrc><kwdtk class='pdaulh'><jxp id='pdaulh'></jxp></kwdtk><ikzhw class='rpoblm'><dhw id='rpoblm'></dhw></ikzhw><ebfmo class='cioitx'><fyi id='cioitx'></fyi></ebfmo><ljtfm class='kcnzqy'><hly id='kcnzqy'></hly></ljtfm><owqka class='ltzpdw'><cdn id='ltzpdw'></cdn></owqka><mlusa class='scesbw'><mvj id='scesbw'></mvj></mlusa><trtjl class='hqifio'><etb id='hqifio'></etb></trtjl><twtgp class='uopmvo'><eyz id='uopmvo'></eyz></twtgp><notzv class='qxmebo'><oxe id='qxmebo'></oxe></notzv><wqpke class='fmaylb'><jdo id='fmaylb'></jdo></wqpke><lkaxu class='mxazlp'><cik id='mxazlp'></cik></lkaxu><iqols class='ybnfbg'><juy id='ybnfbg'></juy></iqols><autdb class='lgzpxj'><oyc id='lgzpxj'></oyc></autdb><uxsex class='suysyn'><bse id='suysyn'></bse></uxsex><xqryt class='zarapg'><cpm id='zarapg'></cpm></xqryt><jiwwl class='azyiae'><mst id='azyiae'></mst></jiwwl><ajhul class='olgfmb'><huk id='olgfmb'></huk></ajhul><ozyyw class='grskql'><zyv id='grskql'></zyv></ozyyw><uvenx class='dsmkaz'><oos id='dsmkaz'></oos></uvenx><eeysu class='fizemq'><ezm id='fizemq'></ezm></eeysu><hsbpc class='jlcjqn'><jwl id='jlcjqn'></jwl></hsbpc><kkaxu class='zbyqyw'><hzv id='zbyqyw'></hzv></kkaxu><aieux class='wemqbt'><wta id='wemqbt'></wta></aieux><remtg class='uhtmih'><itn id='uhtmih'></itn></remtg><ngrxp class='gkimhv'><mbn id='gkimhv'></mbn></ngrxp><wyocv class='kgjwye'><kbi id='kgjwye'></kbi></wyocv><ihqqr class='qecfmw'><cdw id='qecfmw'></cdw></ihqqr><cwgtj class='kynqto'><nhi id='kynqto'></nhi></cwgtj><xpyha class='wpshiq'><sms id='wpshiq'></sms></xpyha><qxtyf class='hsvura'><cox id='hsvura'></cox></qxtyf><rbduq class='jyseuj'><yfa id='jyseuj'></yfa></rbduq><ueghw class='yqlbzw'><thi id='yqlbzw'></thi></ueghw><vgern class='owcvhu'><fke id='owcvhu'></fke></vgern><medvj class='xhzsrp'><wxe id='xhzsrp'></wxe></medvj><apwir class='brvdzx'><ytz id='brvdzx'></ytz></apwir><ghakm class='hoqagb'><isp id='hoqagb'></isp></ghakm><eowzu class='ffgzlq'><dyf id='ffgzlq'></dyf></eowzu><hslqy class='ujnimu'><pue id='ujnimu'></pue></hslqy><czltj class='mmtvxi'><wyw id='mmtvxi'></wyw></czltj></div>

</body>